ArticleNPJ precision oncology2026
Integrating handcrafted and deep learning MRI signatures: an interpretable framework for predicting chemotherapy benefit in glioma.
Article in NPJ precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The molecular and spatial heterogeneity of gliomas severely limits accurate prediction of postoperative adjuvant chemotherapy efficacy, representing a critical bottleneck in achieving personalized treatment decisions. Conventional imaging assessments and single-modality AI models struggle to comprehensively characterize the complex tumor phenotype. Based on preoperative multimodal MRI data from the TCGA-LGG cohort integrated with clinical and survival information from the Genomic Data Commons (GDC), this study extracted 726 radiomics features. Postoperative chemotherapy benefit was operationalized using overall survival (≥24 months vs. <24 months), a pragmatic surrogate endpoint validated in prior low-grade glioma radiomics studies. Two types of deep learning embedding features were generated using segmentation-guided 3D bounding-box and patch-based sampling strategies, combined with a lightweight 3D CNN and a pretrained 3D ResNet-18 (MedicalNet) model. Prediction models were constructed using radiomics alone, deep learning alone, and their fusion, and were evaluated through stratified cross-validation on both a real-world dataset (Dataset 1) and a dataset augmented via PCA-GMM (Dataset 2). Model interpretability was assessed using SHAP attribution analysis, variance analysis, and Grad-CAM visualization. Radiomics and deep learning features exhibited significant information complementarity: the former focused on describing overall tumor volume, morphology, and macro-texture, while the latter excelled at capturing local heterogeneity and subtle spatial infiltration patterns. The fusion model demonstrated optimal performance in predicting postoperative chemotherapy benefit, achieving an AUC of 0.75 on the constrained real-world dataset (Dataset 1) and improving to 0.99 on the more feature-diverse Dataset 2. SHAP analysis revealed key radiomics features driving model predictions, whereas Grad-CAM heatmaps localized model attention to tumor core regions and infiltrative margins-areas highly consistent with the pathological microenvironment associated with drug efficacy. The dual-dataset comparison further confirmed that data quality and feature diversity are core drivers for unleashing model predictive potential and enabling precise drug response phenotyping. This study establishes a transparent and interpretable multimodal AI framework that integrates handcrafted and deep learning MRI features, significantly enhancing the prediction of postoperative chemotherapy benefit in gliomas.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.